The antibody PLT012 targets the fat transporter CD36 to restore immune responses in tumors, offering a new and promising approach to treating immunotherapy-resistant cancers. A new study from Ludwig Cancer Research has uncovered a key mechanism by which immune cells within tumors take up fat, a process that functions as a metabolic checkpoint, suppressing the [...]from SciTechDaily https://ift.tt/Aq9cpGb
